Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Conduit Pharmaceuticals ( (CDT) ) has provided an announcement.
Conduit Pharmaceuticals is actively addressing Nasdaq compliance issues related to market value requirements. On February 11, 2025, the company presented a compliance plan to the Nasdaq Hearing Panel after failing to meet listing rules, with a decision expected soon. As part of its efforts to satisfy Nasdaq’s requirements and reduce debt, the company paid off the remaining portion of a Senior Note to Nirland Limited on February 13, 2025, freeing its assets from liens.
More about Conduit Pharmaceuticals
YTD Price Performance: -80.90%
Average Trading Volume: 3,447,785
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.77M
For a thorough assessment of CDT stock, go to TipRanks’ Stock Analysis page.
